Post by Allen on Jul 29, 2014 22:45:44 GMT -8
De-methylators
These drugs act directly on the DNA in genes, and may encourage tumor regression. There are two drugs in this class approved for other uses: Azacitidine (Vidaza) and Decitabine (Dacogen).
Here are some references:
• Targeting the Unique Methylation Pattern of Androgen Receptor (AR) Promoter in Prostate Stem/Progenitor Cells with 5-Aza-2′-deoxycytidine (5-AZA) Leads to Suppressed Prostate Tumorigenesis
• Novel Epigenetic Target Therapy for Prostate Cancer: A Preclinical Study
Here’s a lab study that combines a de-methylator, a somatastatin (see thread), and an HDACi (see thread):
Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Safety
This class of drugs is associated with numerous serious adverse reactions including anemia, immune suppression, hepatic and renal toxicity, hypokalemia, congestive heart failure, etc.
These drugs act directly on the DNA in genes, and may encourage tumor regression. There are two drugs in this class approved for other uses: Azacitidine (Vidaza) and Decitabine (Dacogen).
Here are some references:
• Targeting the Unique Methylation Pattern of Androgen Receptor (AR) Promoter in Prostate Stem/Progenitor Cells with 5-Aza-2′-deoxycytidine (5-AZA) Leads to Suppressed Prostate Tumorigenesis
• Novel Epigenetic Target Therapy for Prostate Cancer: A Preclinical Study
Here’s a lab study that combines a de-methylator, a somatastatin (see thread), and an HDACi (see thread):
Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Safety
This class of drugs is associated with numerous serious adverse reactions including anemia, immune suppression, hepatic and renal toxicity, hypokalemia, congestive heart failure, etc.
